Treatment
Monoclonal antibody clinical trials
We’re tracking 156 recruiting studies that include Monoclonal antibody, each written for real people, not researchers, below.
Recruiting studies
- NCT06791512RecruitingPhase 3
Chemo Plus Targeted Therapy With or Without Immunotherapy for Colorectal Cancer
This trial compares a standard chemotherapy combination (mFOLFOX6) plus a targeted drug (bevacizumab) with or without an immunotherapy (PD-1 antibody) for locally advanced colorectal cancer. It aims to see if adding the immunotherapy improves outcomes for patients with a specific tumor type (pMMR/MSS).
Guangzhou, GuangdongAges 18–80 - NCT06892223RecruitingPhase 2
Anti-NKG2A antibody for leukemia or MDS after half-matched transplant
This trial tests a drug that targets NKG2A, a protein that may help prevent cancer cells from hiding from the immune system. It is for people with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or related conditions who have already received a half-matched stem cell transplant (haploidentical transplant) with a specific anti-rejection drug plan.
Genova, GENOVAAges 18–99 - NCT07362199RecruitingPhase 2
New combo treatment for chronic ITP
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07674732RecruitingPhase 2
Shorter radiation with immunotherapy for rectal cancer
This trial tests a shorter course of radiation followed by a combination of chemotherapy, immunotherapy, and a targeted drug (bevacizumab) for locally advanced rectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). The goal is to see if this approach can shrink the tumor enough for surgery while avoiding more extensive radiation.
Guangzhou, GuangdongAges 18–75 - NCT06437509RecruitingPhase 2
Study of BL-B01D1 plus immunotherapy for extensive-stage small cell lung cancer
This trial tests a new drug combination—BL-B01D1 plus a PD-1 immunotherapy—for people who have just been diagnosed with extensive-stage small cell lung cancer and have not had any prior treatment for it. The goal is to see if this combination can help shrink or control the cancer better than standard therapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07644897RecruitingPhase 2
Thymosin Alpha 1 Plus Anti-PD-1 for Advanced Melanoma in Older Adults
This trial tests a combination of two drugs—thymosin alpha 1 (an immune-boosting protein) and an anti-PD-1 antibody (a cancer immunotherapy)—in patients 60 and older with advanced melanoma that cannot be surgically removed. The goal is to help the immune system fight the cancer more effectively.
Guangzhou, GuangdongAges 60 years+ - NCT06471205RecruitingPhase 2
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06437522RecruitingPhase 2
New drug combo for recurrent head and neck cancer
This trial tests a new drug combination (BL-B01D1 plus a PD-1 inhibitor) for people with advanced head and neck cancer or other solid tumors that have come back or spread. It aims to see if the treatment can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06657391RecruitingPhase 2
Study of a new drug to prevent graft-versus-host disease in thalassemia patients
This trial tests a drug called an anti-CD25 antibody to see if it can prevent graft-versus-host disease (a condition where donor cells attack the body) in people with transfusion-dependent thalassemia who are getting a stem cell transplant from a partially matched or unrelated donor.
Maoming, GuangdongAges 3–20 - NCT07005570RecruitingPhase 2
Short radiation and chemo with or without immunotherapy for rectal cancer
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) and a targeted therapy (bevacizumab) to short-course radiation followed by chemo can improve outcomes for patients with locally advanced rectal cancer that is pMMR/MSS. The goal is to shrink the tumor before surgery and possibly avoid the need for more extensive treatment.
Guangzhou, GuangdongAges 18–75 - NCT06475300RecruitingPhase 2
BL-B01D1 plus immunotherapy for advanced lung and throat cancers
This trial tests a new combination treatment (BL-B01D1 plus a PD-1 inhibitor) for people with advanced lung cancer or nasopharyngeal cancer. It aims to see if the combination is safe and effective for patients whose cancer has not responded to earlier treatments.
Guangzhou, GuangdongAges 18 years+ - NCT06008054RecruitingPhase 2
New drug combo for advanced gastrointestinal cancers
This trial tests two new drugs (BL-B01D1 and SI-B003) alone or with a standard immunotherapy for advanced gastrointestinal cancers. The goal is to see if these combinations shrink tumors and are safe.
Beijing, Beijing MunicipalityAges 18–75 - NCT05631886RecruitingPhase 1
Testing a cancer vaccine plus immune therapy for hard tumors
This early-phase trial tests whether combining a lab-made CAR-DC cancer vaccine with immune checkpoint medicines can shrink tumors that have specific genetic changes. It’s meant for people with advanced or returning (relapsed) solid tumors or certain lymphomas that match required tumor markers.
Beijing, Beijing MunicipalityAges 18–75 - NCT07292168RecruitingPhase 1/Phase 2
Study of a new antibody for advanced tumors with FGFR1 protein
This trial tests an experimental antibody, OM-RCA-01, in people with advanced solid tumors that have high levels of a protein called FGFR1. It aims to see if the drug is safe and effective for those who have already tried other treatments.
Kazan'Ages 18 years+ - NCT06459648Recruiting
Can anti-CGRP antibodies prevent chronic migraine?
This study tests a new treatment (anti-CGRP antibodies) to prevent migraine attacks from becoming chronic. It looks at whether we can predict who will respond best, aiming to find better long-term control for people with frequent or chronic migraine.
Zaragoza, AragonAges 18–65 - NCT07637448RecruitingPhase 2
EGFR-targeted therapy plus immunotherapy for advanced lung cancer
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
Guangzhou, GuangdongAges 18 years+ - NCT07365592RecruitingPhase 1/Phase 2
Neoadjuvant therapy for locally advanced colorectal cancer
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT06556199RecruitingPhase 1/Phase 2
Study of selinexor combo for returning brain lymphoma
This trial tests a new combination of drugs (selinexor, temozolomide, and an immunotherapy) for people whose primary central nervous system lymphoma has come back or stopped responding to previous treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Hanzhou, ZhejiangAges 18–75 - NCT06259721RecruitingPhase 2
New drug combo for advanced nasopharyngeal cancer after platinum failure
This trial tests a combination of three drugs—an anti-PD1 immunotherapy, nimotuzumab (targets EGFR), and capecitabine (chemotherapy)—for people whose nasopharyngeal cancer has returned or spread and no longer responds to platinum-based chemotherapy. The goal is to see if this combination can help when standard treatment stops working.
Nanchang, JiangxiAges 18–70 - NCT05204147RecruitingPhase 1
Radioactive antibody for CEA-making advanced cancers
This early-phase trial tests a radioactive antibody (Ac225-DOTA-M5A) that targets CEA, a protein found on many cancer cells. It's for people with advanced or metastatic cancers that produce CEA and who have no good standard treatment options left.
Duarte, CaliforniaAges 18 years+ - NCT06468280RecruitingPhase 2
Immunotherapy and chemo with surgery for limited-spread stomach cancer
This trial tests a combination of an immunotherapy drug (PD-1 antibody) plus chemotherapy or targeted therapy, followed by surgery, for people with stomach cancer that has spread to a limited number of other sites. The goal is to see if this approach can help shrink the cancer enough to make surgery more effective.
Shanghai, Shanghai CityAges 18–79 - NCT07523737RecruitingPhase 2
Combination drug trial for relapsed brain lymphoma
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07017829RecruitingPhase 2
Combination therapy for STK11-mutant lung cancer
This trial tests a new drug (GT103) combined with the approved immunotherapy drug pembrolizumab for people with advanced lung cancer that has a specific genetic change (STK11). The goal is to see if adding GT103 helps control the cancer better than pembrolizumab alone.
Buffalo, New YorkAges 18 years+ - NCT07771855RecruitingPhase 2
Antibody treatment for chronic lung disease after stem cell transplant
This study tests a new antibody medicine called tezelumab for patients who develop a breathing problem called bronchiolitis obliterans syndrome (BOS) after a stem cell transplant. The trial aims to see if this medicine can reduce flare-ups and improve lung function.
BesançonAges 18 years+
Common questions
- Are there clinical trials studying Monoclonal antibody?
- Yes. Clin2 currently lists 156 recruiting studies that include Monoclonal antibody, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Monoclonal antibody trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Monoclonal antibody an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Monoclonal antibody or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.